The latest findings from the BREAKWATER study, a phase 3 clinical trial, have shown significant strides in improving treatment outcomes for patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC). Presented by Scott Kopetz, MD, of MD Anderson Cancer Center, this study focused on the combination of encorafenib and cetuximab (EC) with FOLFOX chemotherapy versus standard … Continue reading Encorafenib + cetuximab (EC) BREAKWATER Study Reveals Breakthrough in Treating BRAF V600E-Mutant Metastatic Colorectal Cancer